Skip to main content

Venture the Path Less TraveledTM

A healthcare venture capital firm rooted in the Midwest

Arboretum Ventures News

Arboretum Ventures Exceeds Target with $268 Million Sixth Fund

Arboretum Ventures icon

Improving patient outcomes, reducing healthcare costs

Our progressive strategy of investing in under-ventured geographies and sectors, coupled with our expertise in building deep relationships with entrepreneurs, executives, and investment partners across the healthcare industry, are significant factors contributing to our success.

View our portfolio
medical devices icon
Medical Devices
life science tools icon
Life Science Tools
& Diagnostics
tech-enabled care delivery icon
Care Delivery
pharma adjacencies icon


We seek innovations that solve (big) healthcare problems and make a transformational impact from teams who are diverse in thought, geography, and demographics.


We have a proven formula for identifying early-stage startups that can create value in a capital-efficient manner, accelerate portfolio value, and deliver superior returns.

Portfolio Spotlight

We invest in today’s ideas to forge a path for better healthcare tomorrow

Where NeuMoDx started?
Molecular diagnostics is one of the fastest-growing segments within the in-vitro diagnostics market, but existing systems are expensive, complex, and lack sophisticated automation. Through a unique combination of automation and microfluidics, the NeuMoDx Molecular clinical PCR systems offer best-in-class ease of use, throughput, and cost per test.

Where NeuMoDx is today?
Arboretum collaborated with the team to set the strategic direction that helped accelerate the company’s product development timeline and helped recruit new investors. Since Arboretum’s investment, NeuMoDx gained regulatory approvals for its first assays, launched its product, and in September 2020, QIAGEN acquired NeuMoDx to strengthen its portfolio of automated molecular testing.

Ready to grow with us?
laboratory scientists
NewMoDX logo

We fuel the future of healthcare

under management across six funds
of the portfolio invested in under-ventured markets over 20 years
of all active companies have either a female / minority CEO or founder
patient - lives impacted
View portfolio

Shifting the venture capital paradigm

We are proud to be a Midwest venture capital firm operating with transparency, integrity, and approachability to help you realize your entrepreneurial and investor goals. Together, we’ll positively impact patients, communities, and healthcare.

Meet your team
Arboretum Ventures Senior Team


Tim Petersen brings a wealth of healthcare expertise and relationships to our company and is a very effective member of our Board of Directors. He rolls up his sleeves to assist us when it’s truly needed and has the good sense to stay out of the way when it’s not.

Lou SilvermanCEO Hicuity Health

As our Chairman, Paul McCreadie’s integrity, character, and talent creates a solid foundation of trust, which is essential for effective strategic thinking and decision making. I know that whether things are going well, or if we are facing challenges, I can always count on his collaborative, shoulder to shoulder support and entrepreneurial insight.

Mark ForchetteCEO Delphinus Medical Technologies

Jan Garfinkle has been a valued partner since the early formation of Strata. Her reputation in the business and deep network helped us attract an experienced syndicate of investors and has opened doors to strategic partners vital for our success.

Dan RhodesCEO Strata Oncology

Arboretum Ventures understands the importance of collaboration and passion in building a great company. Their expertise in clinical and reimbursement strategy along with a broad industry network were invaluable in fostering our success.

Surbhi SarnaCEO nVision Medical

Tom Shehab and the supporting Arboretum team provided not only the capital we needed, but also strategic advice, access to an extensive network of potential partners, and unceasing encouragement. Their support has brought out the best in our team and allowed us to focus on our vision of making neuromodulation therapies accessible and easier to use for millions of patients worldwide.

Jill SchiaparelliCEO Avation Medical

In the News

November 21, 2023 in Avation Medical, Home Page, News Page

Study Published in Urology Confirms Efficacy and Safety of Avation Medical’s Noninvasive Vivally® System for OAB

Avation Medical, Inc., an innovative neuromodulation and digital health company with a mission to make wearable peripheral neuromodulation accessible to patients across a variety of clinical conditions, today announced the…
Read More
November 8, 2023 in Home Page, News Page, Strata Oncology

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

Strata Oncology, a next-generation precision oncology company enabling smarter cancer treatment, today announced that it is the recipient of the “Diagnostics Innovation Of The Year” award in the third annual…
Read More
October 31, 2023 in News Page, ViaLase

ViaLase Completes Enrollment for the Pivotal VIA-002 Trial of the ViaLase® Laser to Treat Primary Open Angle Glaucoma

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced it has completed enrollment of VIA-002, the company's pivotal trial of…
Read More